| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered(1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | ||||||||||||||||
| Equity | Common Shares, without par value, issuable under the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan | Other | 9,500,000(2) | $3.58(3) | $ 34,010,000(3) | 0.00014760 | $ | 5,019.88 | |||||||||||||||
| Total Offering Amounts | $ | 34,010,000 | $ | 5,019.88 | |||||||||||||||||||
| Total Fee Offsets | — | ||||||||||||||||||||||
| Net Fee Due | $ | 5,019.88 | |||||||||||||||||||||
| (1) | In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. | ||||
| (2) | Represents 9,500,000 common shares, without par value (the “Common Shares”), of Arbutus Biopharma Corporation available for issuance under the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan. | ||||
| (3) | Estimated solely for the purpose of calculating the registration fee under Rule 457(c) and (h) of the Securities Act on the basis of the average of the high and low sales price per Common Share on August 7, 2024, as reported on the Nasdaq Global Select Market. | ||||